Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs
This guidance document applies to all biologic drug submissions where the sponsor seeks authorization for sale based on demonstrated similarity to a previously approved biologic drug and relies, in part, on prior information regarding that biologic drug in order to present a reduced clinical and non-clinical package as part of the submission.
- Publisher
- Health Canada
- Resources
- 2
- Catalogue metadata updated
- 2022-06-07
Data overview
- Formats
- HTML
- File languages
- English, French